Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24172307 | 0.79 | CA12 (0.39) | HDAC6HDAC1HDAC2CA14CTSK | |
| SCHEMBL4061706 | 0.79 | TDP1 (0.42) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL21937996 | 0.78 | CA14 (0.41) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL9434880 | 0.76 | HDAC6 (0.44) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL8887438 | 0.76 | HDAC1 (0.40) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL9901110 | 0.75 | CA14 (0.44) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL5214651 | 0.74 | HDAC6 (0.34) | HDAC6HDAC1HDAC2CA14CTSS | |
| SCHEMBL929384 | 0.73 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA14CTSS | |
| SCHEMBL9434997 | 0.72 | CA14 (0.43) | HDAC6HDAC1HDAC2CA14L3MBTL1 | |
| SCHEMBL25074829 | 0.72 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA14L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049543-B1 | ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | CALLAGHAN INNOVATION RES LTD (NZ) | 2014-11-05 | — | — | EP | disclosed |
| US-8383636-B2 | Acyclic amine inhibitors of 5-methytioadenosine phosphorylase and nucleosidase | INDUSTRIAL RESEARCH LIMITED (NZ) | 2013-02-26 | — | — | US | disclosed |
| US-20110046167-A1 | ACYCLIC AMINE INHIBITORS OF 5-METHYTIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046167-A1 | ACYCLIC AMINE INHIBITORS OF 5-METHYTIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | MTAP, PNP, TYMP | HDAC6 1023/4885HDAC1 715/4885HDAC2 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.